Your search matched 9 results
While federal drug pricing reform in the Build Back Better Act (BBBA) is stalled at the Senate, states are taking the issue into their own hands.
ICER Policy Proposals for Orphan Drug Pricing | Blog
The Institute for Clinical and Economic Review (ICER) recently published the white paper “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.”
What the lecanemab Approval Means for the Life Science Industry | Blog
The Food and Drug Administration (FDA) approved Alzheimer’s disease (AD) drug lecanemab through its accelerated approval program.
Why the New CMS Oncology Model is an Inflection Point in Advancing Health Equity | Blog
On July 1st, The Centers for Medicare & Medicaid Services, through its Center for Medicare & Medicaid Innovation (CMMI), announced its newest voluntary oncology payment model, Enhancing Oncology Model (EOM).
In July, the Institute for Clinical and Economic Review (ICER) published its final evidence report for bluebird bio’s Zynteglo (betibeglogene autotemcel or “beti-cel”) for the treatment of beta thalassemia, a rare, debilitating blood disorder.
What the CMS National Coverage Decision Means for the Life Science Industry | Blog
What the CMS National Coverage Decision Means for the Life Science Industry
With a global pandemic, rising inflation, and continued political pressures, drug pricing will undoubtedly remain a big focus in 2022.
Health Equity, Real-World Evidence: A Trend to Watch | Blog
The Biden administration cited health equity as one of its top 5 health priorities in a Health Affairs blog.
Already have a RSS feed reader?
